Identification of residues mediating homotropic regulation in human hexokinase 3 reveals a common allosteric interface shared with hexokinase 1
Archives of Biochemistry and Biophysics · 2025
DOI: 10.1016/j.abb.2025.110517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Carolin Freye und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Laboratories of Molecular Recognition, Florida State University, 95 Chieftan Way, Tallahassee, FL, 32306, U…. Hauptthemen laut MEDLINE: Hexokinase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH National Institute of General Medical Sciences, National Institutes of Health.
Abstract (Originalsprache)
Vertebrate hexokinases (HKs) display a variety of allosteric phenomena, including activation and inhibition by both homotropic and heterotropic ligands. The extent to which these homologs share a common allosteric mechanism is unknown. A unique trait of the vertebrate hexokinase 3 (HK3) orthologs is substrate inhibition by glucose. Here, we demonstrate that the isolated, regulatory N-terminal domain of human HK3 contains a low affinity glucose binding site whose dissociation constant (3.2 ± 0.4 mM) approximates the Ki value for glucose (11 ± 2 mM) observed in assays of the full-length enzyme. The isolated, catalytic C-terminal domain harbors a high affinity glucose binding site whose dissociation constant (6.2 ± 0.6 μM) resembles the Km value for glucose (53 ± 1 μM). Substitution of Asn221 in full-length HK3, which lies within the N-terminal glucose binding site, reduces substrate inhibition by 30-fold while leaving other steady-state kinetic parameters unchanged. Homotropic inhibition of HK3 is largely independent of ATP concentrations, in contrast to heterotropic inhibition of hexokinase 1 (HK1) by glucose 6-phosphate, which is competitive with respect to ATP. Adding a 10-fold molar excess of the N-terminal domain to the C-terminal domain fails to alter substrate inhibition, suggesting that interdomain communication in HK3 requires their physical connection. Disrupting a coulombic interaction between N-terminal residue Asp264 and C-terminal residue Arg807, two conserved residues previously shown to participate in HK1 regulation, attenuates glucose inhibition of HK3. Our data support a common allosteric interface in HK1 and HK3, wherein effector binding at spatially distinct sites within the regulatory N-terminus is communicated to the catalytic C-terminus via conserved coulombic residues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, Laboratories of Molecular Recognition, Florida State University, 95 Chieftan Way, Tallahassee, FL, 32306, USA.
- Department of Chemistry and Biochemistry, Laboratories of Molecular Recognition, Florida State University, 95 Chieftan Way, Tallahassee, FL, 32306, USA. Electronic address: bgmiller@fsu.edu.
Förderung
- NIGMS NIH HHS
- NIH National Institute of General Medical Sciences
- National Institutes of Health
Zitieren
APA
Freye, C., & Miller, B. G. (2025). Identification of residues mediating homotropic regulation in human hexokinase 3 reveals a common allosteric interface shared with hexokinase 1. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2025.110517
Vancouver
Freye C, Miller BG. Identification of residues mediating homotropic regulation in human hexokinase 3 reveals a common allosteric interface shared with hexokinase 1. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2025.110517
BibTeX
@article{Freye2025,
author = {Freye, Carolin and Miller, Brian G},
title = {Identification of residues mediating homotropic regulation in human hexokinase 3 reveals a common allosteric interface shared with hexokinase 1},
journal = {Archives of Biochemistry and Biophysics},
year = {2025},
doi = {10.1016/j.abb.2025.110517}
}
EUVIMED